Brokers Set Expectations for GLSI Q1 Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Greenwich LifeSciences in a research report issued to clients and investors on Tuesday, July 21st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings per share of ($0.30) for the quarter. HC Wainwright currently has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.29) EPS and Q4 2027 earnings at ($0.29) EPS.

Several other analysts also recently issued reports on GLSI. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Wall Street Zen cut shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences stock opened at $14.65 on Wednesday. The firm has a market capitalization of $215.03 million, a PE ratio of -9.33 and a beta of 1.40. Greenwich LifeSciences has a one year low of $7.78 and a one year high of $34.10. The stock’s 50 day moving average price is $22.93 and its 200 day moving average price is $24.55.

Institutional Trading of Greenwich LifeSciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in shares of Greenwich LifeSciences by 4.9% in the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company’s stock worth $2,808,000 after acquiring an additional 13,179 shares in the last quarter. Geode Capital Management LLC grew its stake in Greenwich LifeSciences by 6.7% during the 4th quarter. Geode Capital Management LLC now owns 151,684 shares of the company’s stock valued at $3,187,000 after purchasing an additional 9,568 shares in the last quarter. State Street Corp grew its stake in Greenwich LifeSciences by 19.3% during the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock valued at $2,054,000 after purchasing an additional 15,831 shares in the last quarter. Marshall Wace LLP purchased a new stake in Greenwich LifeSciences during the 2nd quarter worth approximately $509,000. Finally, Bank of New York Mellon Corp increased its holdings in Greenwich LifeSciences by 235.5% during the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after purchasing an additional 32,657 shares during the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.